Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C ≤2%) (BeneGene-2)]

A gene therapy study to learn about the effects and safety of fidanacogene elaparvovec in men with hemophilia B

Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C ≤2%) (BeneGene-2)

Category & Conditions: Immune System Diseases and Conditions

Medicine: fidanacogene elaparvovec (PF-06838435)

ClinicalTrials.gov Identifier (NCT): NCT03861273

Protocol ID: C0371002

Print Download

Open Plain Language Summary Result: Click here